Clinical Trials · NCT00075868
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Radiation Therapy Oncology Group
- Enrollment
- 233
- Start date
- Dec 2003
- Locations
- 112 sites, United States
- Primary endpoint
- Prevention of the incidence of moderate, severe, or life-threatening diarrhea